“…However, in an early stage of formulation study, new active pharmaceutical ingredients (APIs) are generally very expensive and its available quantity is very tiny. 2,3) This strictly restricts a number of experiments and makes it difficult to sufficiently investigate the design space of a tableting process. Therefore, if tablets can be successfully prepared from a tiny amount of powder, it is possible to efficiently investigate its design space, resulting in significant cost reduction and speeding up of a new drug development.…”